Table 2. Concentrations of HB-EGF, TGF-α, and amphiregulin, and cell proliferation properties in peritoneal fluid.
|
Concentration of EGF ligands (pg ml−1, mean±s.d.)
|
Proliferation-promoting activities (mean±s.d.)
|
||||
|---|---|---|---|---|---|
| Variable | HB-EGF | TGF-α | Amphiregulin | [3H]Thymidine incorporation (c.p.m.) | WST-1 assay (abs.) |
| Normal ovary (N=18) | 483±495 | 11.12±13.01 | 98±236 | 9216±5777 | 0.12±0.11 |
| Ovarian cyst (N=18) | 653±616 | 7.37±3.67 | 186±322 | 8990±5381 | 0.26±0.18 |
| Ovarian cancer, stage Ia (N=10) | 3090±2286* | 7.45±4.01 | 214±183 | 21 747±8678** | 0.71±0.29*** |
| Ovarian cancer, stage Ic–II (N=13) | 2132±1394* | 8.33±7.47 | 203±220 | 18 654±4988** | 0.76±0.33*** |
| Ovarian cancer, stage III–IV (N=30) | 2053±1204* | 5.14±0.62 | 225±755 | 24 556±10 152** | 0.86±0.66*** |
| Ovarian cancer, Recurrence (N=10) | 2544±1098* | 2.01±5.12 | 212±175 | 21 035±9755** | 0.78±0.28*** |
*
P<0.01 for comparison of HB-EGF level vs normal ovary.
**
P<0.01 for comparison of c.p.m. count vs normal ovary.
***
P<0.01 for comparison of absorbance vs normal ovary.